Go Pro
→ Your $29.97 book is free today (From Profits Run) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$65.36
-1.4%		$78.06
$48.88
▼
$93.42
$12.77B0.972.90 million shs144,204 shs
GRAIL, Inc. stock logo
GRAL
GRAIL
$121.03
-3.3%		$77.33
$41.50
▼
$126.81
$5.45B3.25960,418 shs247,815 shs
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$114.23
-0.9%		$99.67
$61.22
▼
$116.85
$12.98B0.881.90 million shs58,437 shs
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
$15.96
-2.6%		$14.86
$12.07
▼
$29.23
$12.69B-1.244.36 million shs127,045 shs
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
+0.87%-1.53%-17.56%-5.64%+30.86%
GRAIL, Inc. stock logo
GRAL
GRAIL
+13.92%+56.61%+51.70%+89.94%+168.81%
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
+2.47%+5.05%+5.40%+53.71%+52.33%
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
-0.43%-7.56%+22.60%+16.92%-20.10%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$65.36
-1.4%		$78.06
$48.88
▼
$93.42
$12.77B0.972.90 million shs144,204 shs
GRAIL, Inc. stock logo
GRAL
GRAIL
$121.03
-3.3%		$77.33
$41.50
▼
$126.81
$5.45B3.25960,418 shs247,815 shs
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$114.23
-0.9%		$99.67
$61.22
▼
$116.85
$12.98B0.881.90 million shs58,437 shs
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
$15.96
-2.6%		$14.86
$12.07
▼
$29.23
$12.69B-1.244.36 million shs127,045 shs
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
+0.87%-1.53%-17.56%-5.64%+30.86%
GRAIL, Inc. stock logo
GRAL
GRAIL
+13.92%+56.61%+51.70%+89.94%+168.81%
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
+2.47%+5.05%+5.40%+53.71%+52.33%
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
-0.43%-7.56%+22.60%+16.92%-20.10%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
2.83
Moderate Buy$102.6156.98% Upside
GRAIL, Inc. stock logo
GRAL
GRAIL
2.33
Hold$78.60-35.06% Downside
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
2.62
Moderate Buy$91.20-20.16% Downside
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
2.41
Hold$25.9162.31% Upside

Current Analyst Ratings Breakdown

Latest GRAL, SMMT, BBIO, and HALO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/25/2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingMarket Outperform
9/25/2026
GRAIL, Inc. stock logo
GRAL
GRAIL
Mizuho logo
Mizuho
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$65.00 ➝ $100.00
9/24/2026
GRAIL, Inc. stock logo
GRAL
GRAIL
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
9/23/2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral
9/23/2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral
9/22/2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight
9/22/2026
GRAIL, Inc. stock logo
GRAL
GRAIL
Robert W. Baird logo
Robert W. Baird
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$96.00 ➝ $118.00
9/17/2026
GRAIL, Inc. stock logo
GRAL
GRAIL
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$84.00
9/17/2026
GRAIL, Inc. stock logo
GRAL
GRAIL
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageSector Perform$84.00
9/17/2026
GRAIL, Inc. stock logo
GRAL
GRAIL
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageHold$84.00
9/10/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (D-) ➝ Sell (D)
(Data available from 9/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$502.08M25.45N/AN/A($10.77) per share-6.07
GRAIL, Inc. stock logo
GRAL
GRAIL
$147.17M36.74N/AN/A$66.13 per share1.83
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$1.66B7.79$4.73 per share24.13$0.42 per share271.97
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
N/AN/AN/AN/A$0.85 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-$724.93M-$3.57N/AN/AN/A-97.03%N/A-61.19%10/28/2026 (Estimated)
GRAIL, Inc. stock logo
GRAL
GRAIL
-$408.35M-$9.75N/AN/AN/A-236.95%-15.88%-14.02%11/11/2026 (Estimated)
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$316.89M$3.3534.1412.240.4424.86%260.98%23.91%11/2/2026 (Estimated)
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
-$1.08B-$1.12N/AN/AN/AN/A-168.94%-141.92%10/19/2026 (Estimated)

Latest GRAL, SMMT, BBIO, and HALO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
10/19/2026Q3 2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
-$0.28N/AN/AN/A$0.07 millionN/A
8/10/2026Q2 2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-$0.5756-$0.78-$0.2044-$0.78$220.91 million$243.68 million
8/6/2026Q2 2026
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$1.79$2.28+$0.49$1.90$402.28 million$481.00 million
8/5/2026Q2 2026
GRAIL, Inc. stock logo
GRAL
GRAIL
-$2.66-$2.56+$0.10-$2.56$42.39 million$44.69 million
7/23/2026Q2 2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
-$0.2744-$0.28-$0.0056-$0.28$0.11 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
N/AN/AN/AN/AN/A
GRAIL, Inc. stock logo
GRAL
GRAIL
N/AN/AN/AN/AN/A
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
N/AN/AN/AN/AN/A
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
N/A
1.23
1.17
GRAIL, Inc. stock logo
GRAL
GRAIL
N/A
10.95
10.95
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
13.50
2.71
2.31
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
N/A
6.96
6.96

Institutional Ownership

CompanyInstitutional Ownership
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
99.85%
GRAIL, Inc. stock logo
GRAL
GRAIL
N/A
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
97.79%
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
4.61%

Insider Ownership

CompanyInsider Ownership
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
14.23%
GRAIL, Inc. stock logo
GRAL
GRAIL
1.83%
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
2.50%
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
83.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
839195.49 million167.67 millionOptionable
GRAIL, Inc. stock logo
GRAL
GRAIL
91044.67 million43.85 millionOptionable
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
423113.50 million110.66 millionOptionable
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
265797.75 million131.63 millionOptionable

Recent News About These Companies

Summit Therapeutics (NASDAQ:SMMT) Earns Neutral Rating from HC Wainwright
September 25 at 1:48 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31046986
Summit Therapeutics (NASDAQ:SMMT) Receives "Neutral" Rating from HC Wainwright
September 23 at 8:05 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-summit-therapeutics-nasdaq-smmt-receives-neutral-rating-from-hc-wainwright-2026-09-23/
HARMONi-GI1, a Phase III Trial Featuring Ivonescimab Plus Chemotherapy Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract ...
September 22 at 8:24 AM  |  marketscreener.comM
Barclays Keeps Their Hold Rating on Summit Therapeutics (SMMT)
September 22 at 8:24 AM  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/SMMT/pressreleases/4725481/barclays-keeps-their-hold-rating-on-summit-therapeutics-smmt/
HARMONi-GI1, a Phase III Trial Featuring Ivonescimab Plus Chemotherapy Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer from China, to Be Showcased in Presidential Symposium at ESMO 2026
September 22 at 7:00 AM  |  businesswire.comhttps://www.businesswire.com/news/home/20260922660020/en/HARMONi-GI1-a-Phase-III-Trial-Featuring-Ivonescimab-Plus-Chemotherapy-Compared-to-Durvalumab-Plus-Chemotherapy-in-First-Line-Treatment-of-Patients-with-Advanced-Biliary-Tract-Cancer-from-China-to-Be-Showcased-in-Presidential-Symposium-at-ESMO-2026/
Summit Therapeutics PLC (NASDAQ:SMMT) Given Consensus Recommendation of "Hold" by Brokerages
September 22 at 4:15 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31038888
Summit Therapeutics PLC (NASDAQ:SMMT) Receives Consensus Rating of "Hold" from Analysts
September 22 at 4:13 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-summit-therapeutics-plc-nasdaq-smmt-receives-consensus-rating-of-hold-from-analysts-2026-09-22/
Summit Therapeutics (NASDAQ:SMMT) Stock Price Down 5.8% - Should You Sell?
September 21, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-summit-therapeutics-nasdaq-smmt-stock-price-down-58-should-you-sell-2026-09-21/
Engineers Gate Manager LP Makes New Investment in Summit Therapeutics PLC $SMMT
September 20, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-engineers-gate-manager-lp-makes-new-investment-in-summit-therapeutics-plc-smmt-2026-09-20/
Summit Therapeutics: It's Okay Not To Have An Answer
September 17, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4947471-summit-therapeutics-its-okay-not-to-have-an-answer
Analysts Offer Insights on Healthcare Companies: Summit Therapeutics (SMMT) and Azenta (AZTA)
September 15, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/SMMT/pressreleases/4613211/analysts-offer-insights-on-healthcare-companies-summit-therapeutics-smmt-and-azenta-azta/
Summit Therapeutics (NASDAQ:SMMT) Stock Price Down 7% - Should You Sell?
September 15, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-summit-therapeutics-nasdaq-smmt-stock-price-down-7-should-you-sell-2026-09-15/
Updated HARMONi Data Presented at WCLC 2026 Demonstrate Consistent Overall Survival Results with Ivonescimab Plus Chemotherapy in Western and Asian Patients
September 15, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260915307340/en/Updated-HARMONi-Data-Presented-at-WCLC-2026-Demonstrate-Consistent-Overall-Survival-Results-with-Ivonescimab-Plus-Chemotherapy-in-Western-and-Asian-Patients/
Ivonescimab cuts death risk 27% vs. pembrolizumab in lung cancer
September 13, 2026  |  streetinsider.comhttps://www.streetinsider.com/Corporate+News/Ivonescimab+cuts+death+risk+27%25+vs.+pembrolizumab+in+lung+cancer/27054356.html
Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso ...
September 13, 2026  |  streetinsider.comhttps://www.streetinsider.com/Business+Wire/Ivonescimab+Monotherapy+Demonstrates+a+Statistically+Significant+%26amp%3B+Clinically+Meaningful+Benefit+Compared+to+Pembrolizumab+Monotherapy+in+PD-L1-Positive+Advanced+NSCLC+in+Akeso%E2%80%99s+HARMONi-2+Study/27054259.html
Summit’s ivonescimab cuts death risk by 27% versus Keytruda in lung cancer trial
September 13, 2026  |  msn.comhttps://www.msn.com/en-us/news/other/summit-s-ivonescimab-cuts-death-risk-by-27-versus-keytruda-in-lung-cancer-trial/ar-AA2c8ugF
Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso's HARMONi-2 Study Condu
September 13, 2026  |  gurufocus.comhttps://www.gurufocus.com/news/9078710/ivonescimab-monotherapy-demonstrates-a-statistically-significant-clinically-meaningful-benefit-compared-to-pembrolizumab-monotherapy-in-pdl1positive-advanced-nsclc-in-akesos-harmoni2-study-condu
Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso's HARMONi-2 Study Conducted in China
September 13, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260913549808/en/ivonescimab-monotherapy-demonstrates-a-statistically-significant-clinically-meaningful-benefit-compared-to-pembrolizumab-monotherapy-in-pd-l1-positive-advanced-nsclc-in-akeso%e2%80%99s-harmoni-2-study-conducted-in-china/
Hsbc Holdings PLC Purchases Shares of 120,560 Summit Therapeutics PLC $SMMT
September 12, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-hsbc-holdings-plc-purchases-shares-of-120560-summit-therapeutics-plc-smmt-2026-09-12/
Summit Therapeutics PLC (SMMT)
September 10, 2026  |  fr.investing.comhttps://fr.investing.com/equities/summit-therapeutics-plc-news
Summit Therapeutics Shares Rise After Upgrade From Jefferies
September 9, 2026  |  marketscreener.comM

New MarketBeat Followers Over Time

Media Sentiment Over Time

BridgeBio Pharma stock logo

BridgeBio Pharma NASDAQ:BBIO

$65.36 -0.92 (-1.38%)
As of 10:04 AM Eastern
This is a fair market value price provided by Massive. Learn more.

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

GRAIL stock logo

GRAIL NASDAQ:GRAL

$121.03 -4.18 (-3.34%)
As of 10:04 AM Eastern
This is a fair market value price provided by Massive. Learn more.

GRAIL, Inc. operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T. Huber, William H. Rastetter, Mostafa Ronaghi, and Richard D. Klausner on September 11, 2015 and is headquartered in Menlo Park, CA.

Halozyme Therapeutics stock logo

Halozyme Therapeutics NASDAQ:HALO

$114.23 -0.99 (-0.86%)
As of 10:04 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

Summit Therapeutics stock logo

Summit Therapeutics NASDAQ:SMMT

$15.96 -0.42 (-2.55%)
As of 10:04 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas